The inhibitory effect of tongxieyaofang on rats with post infectious irritable bowel syndrome through regulating colonic par-2 receptor

BMC Complementary and Alternative Medicine

Volumn 13, Issue , 2013, Pages

  Hu, Xuguang ^a   Zhang, Xiaojun ^b   Han, Bin ^a   Bei, Weijian ^a  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Irritable bowel syndrome; PAR 2 receptor; Tong Xie Yao Fang

Indexed keywords

ALOSETRON; ANALGESIC AGENT; ANTIDIARRHEAL AGENT; CHINESE DRUG; INTERLEUKIN 6; MESSENGER RNA; PROTEINASE ACTIVATED RECEPTOR 2; SERINE PROTEINASE; TONG XIE YAO FANG; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTIDIARRHEAL ACTIVITY; ARTICLE; COLON MUCOSA; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPERALGESIA; IRRITABLE COLON; MALE; NONHUMAN; PAIN THRESHOLD; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYMPTOM; ULTRAVIOLET SPECTROPHOTOMETRY; UPREGULATION; WITHDRAWAL REFLEX;

ANIMALS; COLON; DEFECATION; DRUGS, CHINESE HERBAL; INTERLEUKIN-6; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, PAR-2; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884735548     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-13-246     Document Type: Article

References (33)

1. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in post infectious IBS. Gastroenterology 2003, 125:1651-1659. 10.1053/j.gastro.2003.09.028, 14724817.
2. Gwee KA, Leong YL, Graham C. The role of psychological and biological factors in post infective gut dysfunction. Gut 1999, 44:400-406. 10.1136/gut.44.3.400, 1727402, 10026328.
3. Spiller R, Garse K. Post infectious irritable bowel syndrome. Gastroen terology 2009, 136:1979-1988.
4. Kok-Ann G, FRCP Ph D. Post-infectious irritable bowel syndrome, an inflammation-immunological model with relevance for other IBS and functional dyspepsia. J Neurogastroenterol Motil 2010, 16:130-134.
5. Spiller R, Garsed K. Infection, inflammation, and the irritable bowel syndrome. J Digestiver Disease 2009, 41:844-849.
6. Fan H, Qiu MY, Mei JJ, Shen GX, Liu SL, Chen R. The study of Tong-Xie-Yao-Fang on 52 cases of D-IBS patients. World J Gastroenterol 2005, 11:4800-4806.
7. Liao H, Banbury LK, Leach DN. Elucidation of DanzhixiaoyaoWan and its constituent herbs on antioxidant activity and inhibition of nitric oxide production. eCAM 2007, 4:425-430. 2176144, 18227909.
8. Xu-guang H, Di X, Yue Z, Xiang-bo Y, Han S. The alleviating pain effect of aqueous extract from Tong-Xie-Yao-Fang, on experimental visceral hypersensitivity and it mechanism. Biol Pharm Bull 2009, 32:1079.
9. Xu-guang H, Zhao-Hui W. The clinic study of Tong-Xie-Yao-Fang on stagnation and spleen deficiency in 35 D-IBS patients. Xinzhongyi 2012, 23:1075-1079.
10. Xu-guang Hu B-H. The effect of Ledebouriella root in Tong-Xie-Yao-Fang. Chinese J Modern Drug Application 2012, 8:46-48.
11. Cenac N, Andrews CN, Holzhausen M, Chapman KG, Beck P, Bunnett NW. Role for protease activity in visceral pain in irritable bowel syndrome. Clin Invest 2009, 117:636-647.
12. Bueno L. Protease activated receptor 2: a new target for IBS treatment. Eur Rev Med Pharmacol Sci 2008, 15:95-102.
13. Sam Ryong J, Walter M, Kimberly L. ICC density predicts bacterial overgrowth in a rat model of post-infectious IBS. World J Gastroenterol 2010, 16:3680-3686. 10.3748/wjg.v16.i29.3680, 2915428, 20677340.
14. Song R, Ping W. The study on quality standard of TongXieYaoFang Granules. Pharm J Chin PLA 2012, 28:154-156.
15. Al-Chaer ED, Kawasaki M, Pasricha PJ. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology 2000, 119:1276-1285. 10.1053/gast.2000.19576, 11054385.
16. Ghoshal UC, Park H, Gwee KA. Bugs and irritable bowel syndrome: the good, the bad and the ugly. J Gastroenterol Hepatol 2010, 25:244-251. 10.1111/j.1440-1746.2009.06133.x, 20074148.
17. Ghoshal U, Ranjan P. Post-infectious irritable bowel syndrome: the past, the present and the future. J Gastroenterology 2011, 8:94-101.
18. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological,and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003, 98:1578-1583. 10.1111/j.1572-0241.2003.07542.x, 12873581.
19. O'Mahony L, Walter J, Komjerly L. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541-551. 10.1053/j.gastro.2004.11.050, 15765388.
20. Cherbut C, Aube AC, Blottiere HM, Galmiche JP. Effects of short-chain fatty acids on gastrointestinal motility. Scand J Gastroenterol 1997, 222:558-561.
21. Nystedt S, Emilsson K, Wahlestedt C, Sundelin J. Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci 2009, 91:9208-9212.
22. Long YQ, Tong JJ, Qian W, Hou XH. Altered expression of intestinal cytokines in development of post infectious irritable bowel syndrome mouse model. Zhonghua Yi Xue Za Zhi 2010, 90:2415-2419.
23. Akiho H, Deng Y, Blennerhassett P, Kanbayashi H, Collins SM. Mechanisms underlying the maintenance of muscle hypercontractility in a model of postinfective gut dysfunction. Gastroenterology 2005, 129:131-141. 10.1053/j.gastro.2005.03.049, 16012943.
24. Gecse K, Róka R, Ferrier L. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008, 57:1035-1037. 10.1136/gut.2008.150821, 18628370.
25. Rana SV, Sharma S, Sinha SK, Parsad KK, Malik A, Singh K. Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients. Trop Gastroenterol 2012, 33:251-256. 10.7869/tg.2012.66, 23923350.
26. Swan C, Duroudier NP, Campbell E, Zaitoun A, Hastings M, Dukes GE, Cox J, Kelly FM, Wilde J, Lennon MG, Neal KR, Whorwell PJ, Hall IP, Spiller RC. Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNF-α. Gut 2013, 62:985-994. 10.1136/gutjnl-2011-301213, 22684480.
27. Scalera A, Minno MNDD, Tarantino G. What does irritable bowel syndrome share with non-alcoholic fatty liver disease?. World J Gastroenterol 2013, 33:5402-5420.
28. Reed DE, Barajas-Lopez C, Cottrell G, Velazquez-Rocha S, Dery O, Grady EF, Bunnett NW, Vanner SJ. Mast cell tryptase and proteinase-activated receptor 2 induce hyperexcitability of guinea-pig submucosal neurons. J Physiol 2003, 547:531-542. 10.1113/jphysiol.2002.032011, 2342663, 12562962.
29. Cenac N, Coelho AM, Nguyen C, Compton S, Ndrade-Gordon P, MacNaughton WK, Wallace Bueno L. Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Clin Pathol 2007, 161:1903-1915.
30. Tanaka Y, Sekiguchi F, Hong H, Kawabata A. PAR-2 triggers IL-8 release via MEK/ERK and PI3-kinase/Akt pathway in GI epithelial cells. Biochem Biophys Res Commun 2008, 377:612-622. 10.1016/j.bbrc.2008.10.017, 18929538.
31. Zhao YB, Li DG. The effect of Tong-Xie-Yao-Fang on neonatal colon irritation induced visceral hypersensitivity. Chinese Traditional Patent Medicine 2010, 28:852-855.
32. Li DH, Li CM, Li WS, Zhou ZD, Zhang Y. The effect of TXYF on restriction stress binding induced IBS rat model. Lishizhen Medicine Maternal Med Res 2009, 12:2036-2040.
33. Liu ZG, Zhao YB. The inhibitory effect of TXYF on the degranulation of mast cells in IBS rats. Modern J Integrated Trad Chin Western Med 2011, 18:1723-1726.